Shares of Humana Inc. (NYSE:HUM – Get Free Report) have been given an average recommendation of “Hold” by the twenty-five research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eighteen have assigned a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $315.33.
HUM has been the subject of several research analyst reports. Bank of America downgraded shares of Humana from a “neutral” rating to an “underperform” rating and lowered their price objective for the company from $376.00 to $247.00 in a research report on Wednesday, October 2nd. JPMorgan Chase & Co. boosted their price target on Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a report on Wednesday, August 21st. Sanford C. Bernstein upgraded Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price objective for the company in a research report on Tuesday, October 8th. Leerink Partners cut Humana from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $400.00 to $250.00 in a research report on Wednesday, October 2nd. Finally, Stephens reissued an “equal weight” rating and issued a $250.00 target price on shares of Humana in a report on Wednesday, October 9th.
Check Out Our Latest Research Report on HUM
Institutional Inflows and Outflows
Humana Stock Performance
HUM opened at $260.73 on Tuesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66. Humana has a 52-week low of $213.31 and a 52-week high of $527.18. The firm has a market cap of $31.39 billion, a P/E ratio of 18.60, a price-to-earnings-growth ratio of 2.04 and a beta of 0.50. The business’s fifty day moving average is $306.51 and its 200-day moving average is $336.35.
Humana (NYSE:HUM – Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.89 by $1.07. The firm had revenue of $29.54 billion for the quarter, compared to the consensus estimate of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same period in the prior year, the company posted $8.94 earnings per share. Sell-side analysts expect that Humana will post 16.06 EPS for the current fiscal year.
Humana Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.36%. The ex-dividend date is Tuesday, December 31st. Humana’s payout ratio is presently 25.25%.
About Humana
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Stories
- Five stocks we like better than Humana
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is a Low P/E Ratio and What Does it Tell Investors?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- 3 REITs to Buy and Hold for the Long Term
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.